Do analysts rate HLS or VGW?

HLS Therapeutics presently has a consensus price target of C$8.00, suggesting a potential upside of 102.53%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe HLS Therapeutics is more favorable than Valens GroWorks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HLS Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Valens GroWorks 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer HLS or CRDL?

HLS Therapeutics currently has a consensus target price of C$8.00, indicating a potential upside of 102.53%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe HLS Therapeutics is more favorable than Cardiol Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HLS Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate HLS or VBV?

HLS Therapeutics presently has a consensus target price of C$8.00, suggesting a potential upside of 102.53%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe HLS Therapeutics is more favorable than VBI Vaccines. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HLS Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 VBI Vaccines 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, HLS or VBV?

HLS Therapeutics has higher revenue and earnings than VBI Vaccines. HLS Therapeutics is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HLS Therapeutics C$56.24M 2.17 -C$15.53M -C$0.27 N/A VBI Vaccines C$3.36M 0.00 -C$62.16M -C$0.97 N/A

HLS Therapeutics (HLS) Competitors

C$3.95 -0.01 (-0.25%)

As of 09/23/2026 04:00 PM Eastern

Compare

HLS vs. VGW, CPH, CRDL, ACB, and VBV

Should you buy HLS Therapeutics stock or one of its competitors? HLS Therapeutics's main competitors and comparable companies include Valens GroWorks (VGW), Cipher Pharmaceuticals (CPH), Cardiol Therapeutics (CRDL), Aurora Cannabis (ACB), and VBI Vaccines (VBV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HLS Therapeutics compare to Valens GroWorks?

HLS Therapeutics (TSE:HLS) and Valens GroWorks (CVE:VGW) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

HLS Therapeutics presently has a consensus price target of C$8.00, suggesting a potential upside of 102.53%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe HLS Therapeutics is more favorable than Valens GroWorks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Valens GroWorks	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

6.1% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled Valens GroWorks'average media sentiment score.

Company	Overall Sentiment
HLS Therapeutics	Neutral
Valens GroWorks	Neutral

Valens GroWorks has a net margin of 0.00% compared to HLS Therapeutics' net margin of -15.26%. Valens GroWorks' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-15.26%	-14.39%	-2.89%
Valens GroWorks	N/A	N/A	N/A

HLS Therapeutics has higher revenue and earnings than Valens GroWorks. Valens GroWorks is trading at a lower price-to-earnings ratio than HLS Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$56.24M	2.17	-C$15.53M	-C$0.27	N/A
Valens GroWorks	C$27.50M	13.96	-C$22.41M	-C$0.18	N/A

Summary

HLS Therapeutics beats Valens GroWorks on 9 of the 14 factors compared between the two stocks.

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

HLS Therapeutics (TSE:HLS) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

HLS Therapeutics has a beta of -0.484581, meaning that its share price is 148% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.045899, meaning that its share price is 5% more volatile than the broader market.

HLS Therapeutics presently has a consensus price target of C$8.00, indicating a potential upside of 102.53%. Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 19.13%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe HLS Therapeutics is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.1% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Cipher Pharmaceuticals had 4 more articles in the media than HLS Therapeutics. MarketBeat recorded 4 mentions for Cipher Pharmaceuticals and 0 mentions for HLS Therapeutics. Cipher Pharmaceuticals' average media sentiment score of 1.22 beat HLS Therapeutics' score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
HLS Therapeutics	Neutral
Cipher Pharmaceuticals	Positive

Cipher Pharmaceuticals has a net margin of 58.81% compared to HLS Therapeutics' net margin of -15.26%. Cipher Pharmaceuticals' return on equity of 22.74% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-15.26%	-14.39%	-2.89%
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

Cipher Pharmaceuticals has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$56.24M	2.17	-C$15.53M	-C$0.27	N/A
Cipher Pharmaceuticals	C$49.62M	7.30	C$11.41M	C$1.12	12.74

Summary

Cipher Pharmaceuticals beats HLS Therapeutics on 11 of the 17 factors compared between the two stocks.

How does HLS Therapeutics compare to Cardiol Therapeutics?

HLS Therapeutics (TSE:HLS) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

HLS Therapeutics currently has a consensus target price of C$8.00, indicating a potential upside of 102.53%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe HLS Therapeutics is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Cardiol Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

HLS Therapeutics has higher revenue and earnings than Cardiol Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$56.24M	2.17	-C$15.53M	-C$0.27	N/A
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.34	N/A

In the previous week, Cardiol Therapeutics' average media sentiment score of 0.64 beat HLS Therapeutics' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
HLS Therapeutics	Neutral
Cardiol Therapeutics	Positive

6.1% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Cardiol Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by insiders. Comparatively, 4.6% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cardiol Therapeutics has a net margin of 0.00% compared to HLS Therapeutics' net margin of -15.26%. HLS Therapeutics' return on equity of -14.39% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-15.26%	-14.39%	-2.89%
Cardiol Therapeutics	N/A	-180.13%	-54.15%

HLS Therapeutics has a beta of -0.484581, suggesting that its share price is 148% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.584931, suggesting that its share price is 42% less volatile than the broader market.

Summary

HLS Therapeutics beats Cardiol Therapeutics on 10 of the 15 factors compared between the two stocks.

How does HLS Therapeutics compare to Aurora Cannabis?

HLS Therapeutics (TSE:HLS) and Aurora Cannabis (TSE:ACB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

6.1% of HLS Therapeutics shares are held by institutional investors. Comparatively, 4.4% of Aurora Cannabis shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aurora Cannabis had 3 more articles in the media than HLS Therapeutics. MarketBeat recorded 3 mentions for Aurora Cannabis and 0 mentions for HLS Therapeutics. Aurora Cannabis' average media sentiment score of 0.73 beat HLS Therapeutics' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company	Overall Sentiment
HLS Therapeutics	Neutral
Aurora Cannabis	Positive

HLS Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$56.24M	2.17	-C$15.53M	-C$0.27	N/A
Aurora Cannabis	C$314.07M	1.17	-C$44.16M	-C$1.94	N/A

HLS Therapeutics has a beta of -0.484581, suggesting that its share price is 148% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.417235, suggesting that its share price is 58% less volatile than the broader market.

Aurora Cannabis has a net margin of -9.53% compared to HLS Therapeutics' net margin of -15.26%. Aurora Cannabis' return on equity of -5.21% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-15.26%	-14.39%	-2.89%
Aurora Cannabis	-9.53%	-5.21%	-1.87%

HLS Therapeutics presently has a consensus target price of C$8.00, suggesting a potential upside of 102.53%. Aurora Cannabis has a consensus target price of C$6.20, suggesting a potential upside of 4.38%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe HLS Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Aurora Cannabis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Aurora Cannabis beats HLS Therapeutics on 9 of the 17 factors compared between the two stocks.

How does HLS Therapeutics compare to VBI Vaccines?

HLS Therapeutics (TSE:HLS) and VBI Vaccines (TSE:VBV) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

HLS Therapeutics has higher revenue and earnings than VBI Vaccines. HLS Therapeutics is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$56.24M	2.17	-C$15.53M	-C$0.27	N/A
VBI Vaccines	C$3.36M	0.00	-C$62.16M	-C$0.97	N/A

HLS Therapeutics presently has a consensus target price of C$8.00, suggesting a potential upside of 102.53%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe HLS Therapeutics is more favorable than VBI Vaccines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
VBI Vaccines	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled VBI Vaccines'average media sentiment score.

Company	Overall Sentiment
HLS Therapeutics	Neutral
VBI Vaccines	Neutral

VBI Vaccines has a net margin of 0.00% compared to HLS Therapeutics' net margin of -15.26%. VBI Vaccines' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-15.26%	-14.39%	-2.89%
VBI Vaccines	N/A	N/A	N/A

6.1% of HLS Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

HLS Therapeutics beats VBI Vaccines on 9 of the 13 factors compared between the two stocks.

Get HLS Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HLS vs. The Competition

Export

Metric	HLS Therapeutics	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$122.19M	C$12.60B	C$7.31B	C$12.84B
Dividend Yield	4.30%	2.63%	2.52%	6.27%
P/E Ratio	-14.63	792.28	274.08	40.36
Price / Sales	2.17	862.22	638.21	9.35
Price / Cash	15.22	88.64	77.80	82.29
Price / Book	2.24	10.59	10.47	4.69
Net Income	-C$15.53M	C$2.81B	C$3.49B	C$299.09M
7 Day Performance	-1.00%	-0.11%	-0.67%	0.01%
1 Month Performance	7.05%	-1.34%	-3.17%	-2.14%
1 Year Performance	-28.31%	2.86%	15.14%	20.17%

HLS Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HLS HLS Therapeutics	N/A	C$3.95 -0.3%	C$8.00 +102.5%	-29.5%	C$122.19M	C$56.24M	N/A	91
VGW Valens GroWorks	N/A	C$3.10 +1.6%	N/A	+0.0%	C$383.88M	C$27.50M	N/A	N/A
CPH Cipher Pharmaceuticals	2.8505 of 5 stars	C$14.30 +0.7%	C$17.00 +18.9%	-12.3%	C$363.43M	C$49.62M	12.77	5	News Coverage Insider Trade
CRDL Cardiol Therapeutics	N/A	C$2.75 -0.7%	N/A	+61.7%	C$321.26M	N/A	N/A	20	High Trading Volume
ACB Aurora Cannabis	1.237 of 5 stars	C$5.17 +0.2%	C$6.20 +19.9%	-14.4%	C$320.32M	C$314.07M	N/A	1,073

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:HLS) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HLS Therapeutics (HLS) Competitors

HLS vs. VGW, CPH, CRDL, ACB, and VBV

How does HLS Therapeutics compare to Valens GroWorks?

Summary

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

Summary

How does HLS Therapeutics compare to Cardiol Therapeutics?

Summary

How does HLS Therapeutics compare to Aurora Cannabis?

Summary

How does HLS Therapeutics compare to VBI Vaccines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLS vs. The Competition

HLS Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HLS Therapeutics (HLS) Competitors

HLS vs. VGW, CPH, CRDL, ACB, and VBV

How does HLS Therapeutics compare to Valens GroWorks?

Do analysts rate HLS or VGW?

Do insiders and institutionals hold more shares of HLS or VGW?

Does the media refer more to HLS or VGW?

Is HLS or VGW more profitable?

Which has higher valuation and earnings, HLS or VGW?

Summary

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

Which has more volatility & risk, HLS or CPH?

Do analysts prefer HLS or CPH?

Do insiders & institutionals believe in HLS or CPH?

Does the media prefer HLS or CPH?

Is HLS or CPH more profitable?

Which has higher valuation and earnings, HLS or CPH?

Summary

How does HLS Therapeutics compare to Cardiol Therapeutics?

Do analysts prefer HLS or CRDL?

Which has preferable valuation and earnings, HLS or CRDL?

Does the media refer more to HLS or CRDL?

Do insiders & institutionals have more ownership in HLS or CRDL?

Is HLS or CRDL more profitable?

Which has more volatility & risk, HLS or CRDL?

Summary

How does HLS Therapeutics compare to Aurora Cannabis?

Do insiders & institutionals believe in HLS or ACB?

Does the media refer more to HLS or ACB?

Which has better earnings & valuation, HLS or ACB?

Which has more risk & volatility, HLS or ACB?

Is HLS or ACB more profitable?

Do analysts prefer HLS or ACB?

Summary

How does HLS Therapeutics compare to VBI Vaccines?

Which has better earnings & valuation, HLS or VBV?

Do analysts rate HLS or VBV?

Does the media prefer HLS or VBV?

Is HLS or VBV more profitable?

Do insiders and institutionals hold more shares of HLS or VBV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLS vs. The Competition

HLS Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools